BRIDGE-SIC Efficacy Trial

ConditionCancer
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorDana-Farber Cancer Institute

About this trial

This is a pragmatic, prospective, randomized clinical trial to test the effectiveness of large language model (LLM)-generated serious illness conversation (SIC) summaries delivered to patients' inpatient and outpatient clinicians at the time of hospital admission on the primary outcome of days in the hospital in the next 90 days.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

DFCI Patients, defined as patients who have a DFCI medical record number.

Admitted to an inpatient solid tumor medical oncology service at BWH (including beds that are considered to be DFCI beds within BWH)

Age ≥ 18 years

Mortality prediction ≥ 25%

Disqualifiers

None

Trial design

Design model

Single group

Treatments tested in this trial

  • LLM-generated SIC summary email to clinical teams

    Behavioral

    An email containing a summary of prior serious illness conversations, generated by a large language model, is sent to the patient's clinical teams at admission, prompting review and discussion of care preferences.

Treatment groups

600 Participants
are divided into 2 treatment groups
Group A: Arm 1: Intervention ArmExperimental treatment 1 intervention
Group B: Arm 2: Control ArmNo intervention 0 interventions

Trial outcomes

Primary outcomes

1

Number of Days in the Hospital

The number of days in the hospital is defined as the total number of inpatient days, including days from the index hospitalization and any subsequent hospital admissions during the follow-up period.

Time frame
90 days after randomization

Secondary outcomes

1

Number of Hospital Readmissions

The number of hospital readmissions is defined as the total number of inpatient hospital readmissions, excluding the index hospitalization.

Time frame
90 days after randomization

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.